Compare BioNTech SE - ADR (BNTX) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs CubeSmart — how do they compare? BioNTech SE - ADR trades at $90.26 (market cap $22.86B), while CubeSmart trades at $41.1 (market cap $9.17B). The key difference: BioNTech SE - ADR is far larger — about 2.5× CubeSmart's market cap, and CubeSmart pays a 5.23% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CUBE | |
|---|---|---|
Market Cap | $22.86B | $9.17B |
Sector | Health | Real Estate |
52-Week High | $119.34 | $42.34 |
52-Week Low | $83.89 | $35.36 |
Enterprise Value | $6.53B | $12.67B |
Dividend Yield | — | 5.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
CubeSmart (CUBE) trades at $40.61, up 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $43.86. The stock shows solid profitability with a 28.93% net income margin and a 5.3% dividend yield, though Q2 2026 earnings are pending. Recent news highlights value comparisons with REIT peers and a scheduled Q2 earnings release on July 30, 2026.
The outlook is cautiously optimistic, supported by strong fundamentals and analyst buy ratings, but risks include high leverage with $2.99B long-term debt and sensitivity to interest rates. Earnings beats in recent quarters provide momentum, yet macroeconomic uncertainty could pressure growth. The stock presents a balanced opportunity for income-focused investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
